Jenburkt Pharmaceuticals
1,142.85
+19.35(+1.72%)
Market Cap₹504.34 Cr
PE Ratio14.27
IndustryHealthcare
Company Performance:
1D+1.72%
1M+9.66%
6M+3.36%
1Y-11.72%
5Y+121.59%
View Company Insightsright
More news about Jenburkt Pharmaceuticals
20May 25
Jenburkt Pharmaceuticals Reports Strong Q4 Results, Announces Dividend
Jenburkt Pharmaceuticals released its Q4 financial results, showing significant growth. Revenue increased by 5.80% to ₹410.50 crore. EBITDA rose by 10.25% to ₹108.60 crore, with the EBITDA margin expanding to 26.45%. Net profit grew by 8.10% to ₹85.40 crore. The company also announced a dividend of ₹18.00 per equity share.
 no imag found
Jenburkt Pharmaceuticals
1,142.85
+19.35
(+1.72%)
1 Year Returns:-11.72%
Industry Peers
Sun Pharmaceutical
1,790.00
(+0.56%)
Divis Laboratories
6,586.00
(-0.16%)
Torrent Pharmaceuticals
4,438.50
(+2.27%)
Cipla
1,399.60
(+0.06%)
Zydus Life Science
1,083.70
(-0.08%)
Dr Reddys Laboratories
1,280.50
(+1.03%)
Lupin
2,272.80
(+1.02%)
Mankind Pharma
2,342.60
(-0.44%)
Aurobindo Pharma
1,467.10
(+0.24%)
Laurus Labs
1,431.00
(+0.27%)